GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (STU:4ZU0) » Definitions » EPS (Diluted)

Biora Therapeutics (STU:4ZU0) EPS (Diluted) : €-6.64 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics EPS (Diluted)?

Biora Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-6.64.

Biora Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was €-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-6.64.

Biora Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was €-0.39. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-7.60.

During the past 3 years, the average EPS without NRIGrowth Rate was 54.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 28.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Biora Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 54.50% per year. The lowest was -29.20% per year. And the median was 35.30% per year.


Biora Therapeutics EPS (Diluted) Historical Data

The historical data trend for Biora Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics EPS (Diluted) Chart

Biora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -146.84 -144.06 -56.93 -118.00 -7.22

Biora Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.49 -1.36 -4.58 -0.57 -0.13

Competitive Comparison of Biora Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Biora Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biora Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's PE Ratio falls into.



Biora Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Biora Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-113.813-0)/15.773
=-7.22

Biora Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.854-0)/29.297
=-0.13

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biora Therapeutics  (STU:4ZU0) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biora Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biora Therapeutics (STU:4ZU0) Business Description

Traded in Other Exchanges
Address
4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Biora Therapeutics (STU:4ZU0) Headlines

No Headlines